Friday, March 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Delta plus variant identified in UK

What is the “delta plus” variant?

It’s a relative of the delta variant, identified by British scientists last month.

Because it isn’t a variant of interest or concern, it has not yet been officially named after a letter of the Greek alphabet, like the other worrisome variants.

Scientists are monitoring the delta-related variant — known as AY.4.2. — to see if it might spread more easily or be more deadly than previous versions of the coronavirus. In a recent report, U.K. officials said this variant makes up 6% of all analyzed COVID-19 cases in the country and is “on an increasing trajectory.”

The variant has two mutations in the spike protein, which helps the coronavirus invade the body’s cells. These changes have also been seen in other versions of the virus since the pandemic started, but haven’t gone very far, Francois Balloux, director of the Genetics Institute at University College London.

The delta variant remains “by far the most dominant variant in terms of global circulation” said Maria Van Kerkhove, the World Health Organization’s technical lead on COVID-19, at a public session this week.

“Delta is dominant, but delta is evolving,” she said, adding that the more the virus circulates, the greater chances it has to mutate.

Source: Modern Healthcare

https://www.modernhealthcare.com/safety-quality/what-delta-plus-variant-coronavirus

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!